287 related articles for article (PubMed ID: 31949157)
1. Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer.
Achinger-Kawecka J; Valdes-Mora F; Luu PL; Giles KA; Caldon CE; Qu W; Nair S; Soto S; Locke WJ; Yeo-Teh NS; Gould CM; Du Q; Smith GC; Ramos IR; Fernandez KF; Hoon DS; Gee JMW; Stirzaker C; Clark SJ
Nat Commun; 2020 Jan; 11(1):320. PubMed ID: 31949157
[TBL] [Abstract][Full Text] [Related]
2. Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance.
Zhou Y; Gerrard DL; Wang J; Li T; Yang Y; Fritz AJ; Rajendran M; Fu X; Stein G; Schiff R; Lin S; Frietze S; Jin VX
Nat Commun; 2019 Apr; 10(1):1522. PubMed ID: 30944316
[TBL] [Abstract][Full Text] [Related]
3. The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer.
Achinger-Kawecka J; Stirzaker C; Portman N; Campbell E; Chia KM; Du Q; Laven-Law G; Nair SS; Yong A; Wilkinson A; Clifton S; Milioli HH; Alexandrou S; Caldon CE; Song J; Khoury A; Meyer B; Chen W; Pidsley R; Qu W; Gee JMW; Schmitt A; Wong ES; Hickey TE; Lim E; Clark SJ
Nat Struct Mol Biol; 2024 Mar; 31(3):498-512. PubMed ID: 38182927
[TBL] [Abstract][Full Text] [Related]
4. Constitutively bound CTCF sites maintain 3D chromatin architecture and long-range epigenetically regulated domains.
Khoury A; Achinger-Kawecka J; Bert SA; Smith GC; French HJ; Luu PL; Peters TJ; Du Q; Parry AJ; Valdes-Mora F; Taberlay PC; Stirzaker C; Statham AL; Clark SJ
Nat Commun; 2020 Jan; 11(1):54. PubMed ID: 31911579
[TBL] [Abstract][Full Text] [Related]
5. Prolactin Drives a Dynamic STAT5A/HDAC6/HMGN2 Cis-Regulatory Landscape Exploitable in ER+ Breast Cancer.
Craig JM; Turner TH; Harrell JC; Clevenger CV
Endocrinology; 2021 May; 162(5):. PubMed ID: 33589921
[TBL] [Abstract][Full Text] [Related]
6. CTCF modulates Estrogen Receptor function through specific chromatin and nuclear matrix interactions.
Fiorito E; Sharma Y; Gilfillan S; Wang S; Singh SK; Satheesh SV; Katika MR; Urbanucci A; Thiede B; Mills IG; Hurtado A
Nucleic Acids Res; 2016 Dec; 44(22):10588-10602. PubMed ID: 27638884
[TBL] [Abstract][Full Text] [Related]
7. A tour of 3D genome with a focus on CTCF.
Wang DC; Wang W; Zhang L; Wang X
Semin Cell Dev Biol; 2019 Jun; 90():4-11. PubMed ID: 30031214
[TBL] [Abstract][Full Text] [Related]
8. Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms.
Bianco S; Gévry N
Transcription; 2012; 3(4):165-70. PubMed ID: 22771991
[TBL] [Abstract][Full Text] [Related]
9. ELF5 modulates the estrogen receptor cistrome in breast cancer.
Piggin CL; Roden DL; Law AMK; Molloy MP; Krisp C; Swarbrick A; Naylor MJ; Kalyuga M; Kaplan W; Oakes SR; Gallego-Ortega D; Clark SJ; Carroll JS; Bartonicek N; Ormandy CJ
PLoS Genet; 2020 Jan; 16(1):e1008531. PubMed ID: 31895944
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
11. SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.
Chan HJ; Li H; Liu Z; Yuan YC; Mortimer J; Chen S
Oncotarget; 2015 Sep; 6(28):25815-27. PubMed ID: 26158350
[TBL] [Abstract][Full Text] [Related]
12. LATS1 controls CTCF chromatin occupancy and hormonal response of 3D-grown breast cancer cells.
Ramírez-Cuéllar J; Ferrari R; Sanz RT; Valverde-Santiago M; García-García J; Nacht AS; Castillo D; Le Dily F; Neguembor MV; Malatesta M; Bonnin S; Marti-Renom MA; Beato M; Vicent GP
EMBO J; 2024 May; 43(9):1770-1798. PubMed ID: 38565950
[TBL] [Abstract][Full Text] [Related]
13. Integrative characterization of G-Quadruplexes in the three-dimensional chromatin structure.
Hou Y; Li F; Zhang R; Li S; Liu H; Qin ZS; Sun X
Epigenetics; 2019 Sep; 14(9):894-911. PubMed ID: 31177910
[TBL] [Abstract][Full Text] [Related]
14. Nuclear-encoded mitochondrial MTO1 and MRPL41 are regulated in an opposite epigenetic mode based on estrogen receptor status in breast cancer.
Kim TW; Kim B; Kim JH; Kang S; Park SB; Jeong G; Kang HS; Kim SJ
BMC Cancer; 2013 Oct; 13():502. PubMed ID: 24160266
[TBL] [Abstract][Full Text] [Related]
15. Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors.
Varešlija D; McBryan J; Fagan A; Redmond AM; Hao Y; Sims AH; Turnbull A; Dixon JM; Ó Gaora P; Hudson L; Purcell S; Hill AD; Young LS
Clin Cancer Res; 2016 Jun; 22(11):2765-77. PubMed ID: 26763249
[TBL] [Abstract][Full Text] [Related]
16. The Eleanor ncRNAs activate the topological domain of the ESR1 locus to balance against apoptosis.
Abdalla MOA; Yamamoto T; Maehara K; Nogami J; Ohkawa Y; Miura H; Poonperm R; Hiratani I; Nakayama H; Nakao M; Saitoh N
Nat Commun; 2019 Aug; 10(1):3778. PubMed ID: 31439835
[TBL] [Abstract][Full Text] [Related]
17. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
[TBL] [Abstract][Full Text] [Related]
18. Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer.
Jia Y; Song Y; Dong G; Hao C; Zhao W; Li S; Tong Z
Sci Rep; 2019 Sep; 9(1):12939. PubMed ID: 31506496
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
Tonsing-Carter E; Hernandez KM; Kim CR; Harkless RV; Oh A; Bowie KR; West-Szymanski DC; Betancourt-Ponce MA; Green BD; Lastra RR; Fleming GF; Chandarlapaty S; Conzen SD
Breast Cancer Res; 2019 Jul; 21(1):82. PubMed ID: 31340854
[TBL] [Abstract][Full Text] [Related]
20. Recurrent mutations at estrogen receptor binding sites alter chromatin topology and distal gene expression in breast cancer.
Yang J; Wei X; Tufan T; Kuscu C; Unlu H; Farooq S; Demirtas E; Paschal BM; Adli M
Genome Biol; 2018 Nov; 19(1):190. PubMed ID: 30404658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
